Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PHILLIP FYMAN AND ALEXANDER WEINGARTEN MD PC

NPI: 1386747947 · JERICHO, NY 11753 · Interventional Pain Medicine Physician · NPI assigned 09/07/2006

$690K
Total Medicaid Paid
24,233
Total Claims
23,061
Beneficiaries
12
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialLABIENIEC, SARA (MANAGER)
NPI Enumeration Date09/07/2006

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,572 $52K
2019 3,527 $87K
2020 3,686 $104K
2021 3,417 $112K
2022 3,311 $94K
2023 4,147 $124K
2024 3,573 $117K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 10,790 10,221 $515K
80305 11,165 10,639 $72K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 717 699 $46K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 272 266 $24K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 785 741 $18K
76942 161 155 $7K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 44 44 $6K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 13 13 $1K
20553 13 13 $1K
J1030 Injection, methylprednisolone acetate, 40 mg 143 142 $397.54
J1010 Injection, methylprednisolone acetate, 1 mg 102 101 $379.11
G8427 Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications 28 27 $0.00